The panel's decision was based almost
entirely on the Jupiter trial, a study funded by Crestors maker, AstraZeneca, that compared a daily dose of Crestor to placebo in nearly 18,000 people who
fit the
description used by the panel (and who would not be eligible for a statin under the current guidelines).